Marjon Hester Cnossen

Marjon Hester Cnossen

Auto-generated profile, based on publicly available information

Marjon Hester Cnossen

Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital University Medical Center Rotterdam Rotterdam The Netherlands

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Blood Reviews
Verified
Journal Article
Closed access
MHM.E. Houwing
M.E. Houwing
PPP.J. de Pagter
P.J. de Pagter
EBEduard J. van Beers
Eduard J. van Beers
BBB.J. Biemond
B.J. Biemond
ERE. Rettenbacher
E. Rettenbacher
MCM.H. Cnossen
M.H. Cnossen

16 October 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
JSJoline L. Saes
Joline L. Saes
MVMarieke J. A. Verhagen
Marieke J. A. Verhagen
KMKarina Meijer
Karina Meijer
MCMarjon H. Cnossen
Marjon H. Cnossen
RSRoger E. G. Schutgens
Roger E. G. Schutgens
SSSaskia E. M. Schols
Saskia E. M. Schols
Patients with hereditary rare bleeding disorders (RBDs) present with diverse hemorrhagic symptoms. Correlation between factor activity levels and clinical bleeding severity is poor for most RBDs. Threshold factor activity levels have been previously described in relation to bleeding severity but have not yet been validated. The Rare Bleeding Disorders in the Netherlands (RBiN) study is a nationwide cross-sectional study of patients registered in all 6 Dutch Haemophilia Treatment Centers with a known RBD and who are age 1 to 99 years. Bleeding scores were determined, and laboratory and clinical data were extracted from patient files. In all, 263 patients were included, of whom 202 (77%) attended the scheduled study visit. The median International Society of Thrombosis and Haemostasis (ISTH) bleeding assessment tool (BAT) score was 9. Correlations between baseline factor activity levels and ISTH BAT scores were strong for deficiencies in factor II (FII) (r = –0.792) and FX (r = –0.838) and were moderate for deficiencies of fibrinogen (r = –0.683), FV (r = –0.623), FVII (r = –0.516), FXIII (r = –0.516), and α2-antiplasmin (r = –0.594). There was no correlation for FXI deficiency (r = –0.218). The RBD BAT identified more women (94% vs 83%) and children (100% vs 71%) with an RBD than the ISTH BAT did. Importantly, 48% of patients had more severe bleeding than predicted for their baseline factor activity level. In addition, 34% of patients were predicted to be asymptomatic, but they actually had grade 2 (31%) or 3 (3%) bleeding. Bleeding severity in patients with RBDs is more pronounced than previously anticipated. The previously determined threshold factor activity levels to ensure no (spontaneous) bleeding in patients with an RBD are inaccurate. This trial was registered at www.clinicaltrials.gov as #NCT03347591.

1 July 2018 in Blood Reviews
Verified
Journal Article
Open access
HHH.C.A.M. Hazendonk
H.C.A.M. Hazendonk
IMI. van Moort
I. van Moort
RMR.A.A. Mathôt
R.A.A. Mathôt
KFK. Fijnvandraat
K. Fijnvandraat
FLF.W.G. Leebeek
F.W.G. Leebeek
MCM.H. Cnossen
M.H. Cnossen
Replacement therapy with clotting factor concentrates (CFC) is the mainstay of treatment in hemophilia. Its widespread application has led to a dramatic decrease in morbidity and mortality in patients, with concomitant improvement of quality of life. However, dosing is challenging and costs are high. This review discusses benefits and limitations of pharmacokinetic (PK)-guided dosing of replacement therapy as an alternative for current dosing regimens. Dosing of CFC is now primarily based on body weight and based on its in vivo recovery (IVR). Benefits of PK-guided dosing include individualization of treatment with better targeting, more flexible blood sampling, increased insight into association of coagulation factor levels and bleeding, and potential overall lowering of overall costs. Limitations include a slight burden for the patient, and availability of closely collaborating, experienced clinical pharmacologists.

16 April 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
MDMyrthe J. van Dijk
Myrthe J. van Dijk
MRMinke A.E. Rab
Minke A.E. Rab
BOBrigitte A. van Oirschot
Brigitte A. van Oirschot
JBJennifer Bos
Jennifer Bos
CDCleo Derichs
Cleo Derichs
EBEduard J. van Beers
Eduard J. van Beers

29 December 2015 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
HHH. C. A. M. Hazendonk
H. C. A. M. Hazendonk
JLJ. Lock
J. Lock
RMR. A. A. Mathôt
R. A. A. Mathôt
KMK. Meijer
K. Meijer
MPM. Peters
M. Peters
MCM. H. Cnossen
M. H. Cnossen
Essentials Targeting of factor VIII values is a challenge during perioperative replacement therapy in hemophilia. This study aims to identify the extent and predictors of factor VIII underdosing and overdosing. Blood group O predicts underdosing and is associated with perioperative bleeding. To increase quality of care and cost‐effectiveness of treatment, refining of dosing is obligatory. Summary Background Perioperative administration of factor VIII (FVIII) concentrate in hemophilia A may result in both underdosing and overdosing, leading to respectively a risk of bleeding complications and unnecessary costs. Objectives This retrospective observational study aims to identify the extent and predictors of underdosing and overdosing in perioperative hemophilia A patients (FVIII levels < 0.05 IU mL−1). Patients and Methods One hundred nineteen patients undergoing 198 elective, minor, or major surgical procedures were included (median age 40 years, median body weight 75 kg). Perioperative management was evaluated by quantification of perioperative infusion of FVIII concentrate and achieved FVIII levels. Predictors of underdosing and (excessive) overdosing were analyzed by logistic regression analysis. Excessive overdosing was defined as upper target level plus ≥ 0.20 IU mL−1. Results Depending on postoperative day, 7–45% of achieved FVIII levels were under and 33–75% were above predefined target ranges as stated by national guidelines. A potential reduction of FVIII consumption of 44% would have been attained if FVIII levels had been maintained within target ranges. Blood group O and major surgery were predictive of underdosing (odds ratio [OR] 6.3, 95% confidence interval [CI] 2.7–14.9; OR 3.3, 95% CI 1.4–7.9). Blood group O patients had more bleeding complications in comparison to patients with blood group non‐O (OR 2.02, 95% CI 1.00–4.09). Patients with blood group non‐O were at higher risk of overdosing (OR 1.5, 95% CI 1.1–1.9). Additionally, patients treated with bolus infusions were at higher risk of excessive overdosing (OR 1.8, 95% CI 1.3–2.4). Conclusion Quality of care and cost‐effectiveness can be improved by refining of dosing strategies based on individual patient characteristics such as blood group and mode of infusion.

24 March 2018 in Haemophilia
Verified
Journal Article
Open access
PDF file
HHH. C. A. M. Hazendonk
H. C. A. M. Hazendonk
JHJ. M. Heijdra
J. M. Heijdra
NJN. C. B. de Jager
N. C. B. de Jager
HVH. C. Veerman
H. C. Veerman
JBJ. Boender
J. Boender
TGthe “OPTI‐CLOT” and “WIN” study group
the “OPTI‐CLOT” and “WIN” study group
Introduction: Patients with Von Willebrand disease (VWD) are regularly treated with VWF‐containing concentrates in case of acute bleeding, trauma and dental or surgical procedures.Aim: In this multicentre retrospective study, current perioperative management with a von Willebrand factor (VWF)/Factor VIII (FVIII) concentrate (Haemate® P) in patients with VWD was evaluated.Patients/Methods: Patients with VWD undergoing minor or major surgery between 2000 and 2015, requiring treatment with a VWF/FVIII concentrate (Haemate® P), were included. Achieved VWF activity (VWF:Act) and FVIII during FVIII‐based treatment regimens were compared to predefined target levels in national guidelines.Results: In total, 103 patients with VWD (148 surgeries) were included: 54 type 1 (73 surgeries), 43 type 2 (67 surgeries) and 6 type 3 (8 surgeries). Overall, treatment resulted in high VWF:Act and FVIII levels, defined as ≥0.20 IU/mL above predefined levels. In patients with type 1 VWD, respectively, 65% and 91% of trough VWF:Act and FVIII levels were higher than target levels. In patients with type 2 and type 3 VWD, respectively, 53% and 57% of trough VWF:Act and 72% and 73% of trough FVIII levels were higher than target level. Furthermore, FVIII accumulation over time was observed, while VWF:Act showed a declining trend, leading to significantly higher levels of FVIII than VWF:Act.Conclusion: High VWF:Act and accumulation of FVIII were observed after perioperative FVIII‐based replacement therapy in patients with VWD, both underlining the necessity of personalization of dosing regimens to optimize perioperative treatment.